ASCO 2023 | The future role of erdafitinib in advanced urothelial carcinoma

Arlene Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, verifies the NORSE trial (NCT03473743) findings with the randomized THOR trial (NCT03390504) for previously treated urothelial cancer. Patients in the THOR trial, who had prior chemotherapy and a prior immune checkpoint inhibitor, were randomized between a single agent taxane and erdafitinib. The objective response rate (ORR) for patients receiving erdafitinib was higher compared to patients receiving single agent taxanes andvinflunine. Median overall survival (OS) and progression-free survival (PFS) were significantly higher in the erdafitinib arm. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.